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ABSTRACT: 
Phage endolysins and bacterial autolysins represent a novel class of antibacterials (enzybiotics) 
against Gram-positive bacteria due to their unique ability to cleave the peptidoglycan in a generally 
species-specific manner. They provide a novel mode of action, kill fast and selectively pathogenic 
bacteria and show low toxicity or propensity to develop resistances. The Skl endolysin is encoded 
by the ΦSK137 bacteriophage of Streptococcus mitis, a human pathogen closely related to 
Streptococcus pneumoniae. It comprises an N-terminal catalytic module (CHAP amidase) and a 
C-terminal choline-binding module (CBM) closely related to that of the LytA amidase, the major 
pneumococcal autolysin. Systematic in-depth characterization of Skl and LytA have allowed the 
construction of two functional chimeric lysins by module swapping. By doing so, we have produced 
a new enzybiotic, QSLA2, that largely overcomes the antibacterial activity of LytA. By contrary, 
neither the chimera QLAS1 nor Skl efficiently lyse the pneumococcus from the outside, in spite of 
their capability to degrade purified cell walls. This variability in antimicrobial activity seems to be 
linked to i) the distinct affinity for choline and choline-induced dimerization showed by the CBMs 
of the parental enzymes, ii) the intrinsic efficiencies of the catalytic modules, iii) restraints imposed 
by the complex structural organization of intact cell walls and iv) the precise orientation of the two 
modules in the overall structure. Taken together, our results provide new clues on the role played by 
the CBM and module combination in the antibactericidal potential of pneumococcal lysins that 
can be used to improve or finely tune their activities.










Cell wall lytic enzymes encoded by bacteriophages 
and bacteria constitute a novel and promising 
class of antimicrobials (enzybiotics). They usually 
consist of at least one catalytic module linked to 
other modules commonly involved in cell wall 
attachment and responsible for their stringent 
substrate specificity [1,2]. With the single exception 
of  Cpl-7 endolysin, in the pneumococcal lytic 
enzymes this function relies on the choline-binding 
modules (CBMs) that specifically recognize 
the choline moieties attached to teichoic and 
lipoteichoic acids [3]. 
The effectiveness as antimicrobials of LytA, the 
major pneumococcal autolysin, and of endolysins 
Cpl-1 and Pal has been already demonstrated 
using different animal models of pneumococcal 
infection [2]. Nevertheless, identification of new 
lysins with high antipneumococcal activity is of 
primary interest. In this context, the Skl endolysin 
encoded by the ΦSK137 bacteriophage of 
Streptococcus mitis constituted a good candidate 
to be tested, as it degrades pneumococcal cell walls 
and comprises a CBM 67% identical in sequence 
to the homologous region of LytA [4]. By contrary 
they have unrelated catalytic modules (CM) with 
N-acetylmuramoyl-L-alanine amidase activities 
(CHAP and Amidase_2 respectively). 
We have characterized the Skl endolysin in 
comparison with LytA, examining the affinity for 
choline and the changes promoted in structure 
and stability by choline recognition. Aiming 
to improve Skl activity and also to test how the 
modules of  these two amidases conditioned 
their antimicrobial activity, we have created two 
chimeric lysins (QLAS1 and QSLA2), by module 
swapping, whose structural and functional 
features have been also investigated, including the 
in vitro antipneumococcal activity. 
2. Experimental Section
2.1. Proteins
Skl and LytA were produced and purified as 
previously described [4-5]. Chimeric lysins were 
built from the genes of  the parental enzymes, 
cloned in a pT7-7 plasmid, using the procedure 
of Wurch et al. [6]. The final constructions were 
overexpressed in Escherichia coli BL21 (DE3) 
and purified using the procedure used for Skl and 
LytA. All protein concentrations were determined 
spectrophotometrically using the theoretical 
extinction coefficients.
2.2. Methods
Choline titration curves of lysins were obtained 
by circular dichroism (DC), following the change 
in ellipticity promoted by choline binding in 
the far- and near-UV regions of the spectrum. 
The association state and its dependence on 
choline binding was analyzed by size-exclusion 
chromatography and ultracentrifugation, whereas 
the structural stability and modular organization 
were evaluated by thermal denaturation 
experiments using DC [5]. In vitro killing assays 
were carried out with different pneumococcal 
strains. Cells were resuspended in PBS, pH 6.8, 
to an OD550nm ≅ 0.6 and incubated at 37ºC for 60 
min with or without the lytic enzymes, added at 
varying concentrations. Evolution of the OD550nm 
was followed at different times and viable cells 
were measured after 15 and 60 min incubation. 
The CLSI protocol [7] was used to determine 
minimal inhibitory concentrations (MIC). 
3. Results 
Titration experiments showed that saturation 
of  choline-binding sites and choline-induced 
dimerization of Skl occurs at ligand concentrations 
20-times higher than those required by LytA. This 
finding could explain their different activities 
on purified cell walls [4], as full activity of 
pneumococcal lysins depends on the interaction 
with this aminoalcohol, and dimerization increased 
around 10-fold LytA activity [5]. To test this 
hypothesis, and taking advantage of the modular 
architecture of both lysins and of the similarity 
of sequences shown by their CBMs, two chimeric 
lysins were constructed by module interchange: 
QLAS1 (CM of LytA fused to the CBM of Skl) 
and QSLA2 (CM of Skl fused to the CBM of 
LytA). The structural and functional features 
of both chimeras were similar but not equals to 
those displayed by their respective modules in the 
parental enzymes, and both degraded isolated cell 
walls. Very different results were obtained however 
in the in vitro killing assays. 
As shown in Fig. 1, only LytA and QSLA2, 
which carried the same CBM, behaved as efficient 
antimicrobials against pneumococcus. By contrary 
neither Skl nor QLAS1 reduced appreciably 
the number of  viable cells under identical 
conditions. Of note, QSLA2 largely overcomes 
the antimicrobial activity of  LytA considering 
both MIC values and cell viability after 15 or 60 
min incubation with the lysins. 
Taken together all these results provide a valuable 
information on the influence that each module 
has on the overall stability of  these lysins and 
their activities than can be applied to modify pre-
existing lysins or to create new ones. 
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